Imfinzi approval gives AstraZeneca a first immunotherapy combination in early bladder cancer
Imfinzi moves into early bladder cancer, but can AstraZeneca turn a DFS win into real-world bladder-preserving impact?
Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer
Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.
Papillary NMIBC could become the next commercial test for ImmunityBio’s ANKTIVA franchise
ANKTIVA already has an NMIBC foothold. The harder test is whether FDA reviewers accept extrapolation into papillary-only disease.
Veracyte’s TrueMRD Medicare win pushes whole-genome MRD testing into bladder cancer surveillance
MRD testing is moving from research to reimbursement. Veracyte now has Medicare coverage, but adoption in bladder cancer care is the harder test.
Can Ferring turn real-world ADSTILADRIN use into a broader NMIBC treatment strategy?
Bladder-sparing therapy needs better sequencing. Ferring’s ADSTILADRIN re-induction signal raises hope, but durability is the real test.
What Natera’s Signatera CDx approval changes for adjuvant Tecentriq use in bladder cancer
MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.
Why ImmunityBio’s Japan BCG Laboratory agreement matters beyond bladder cancer supply
A bladder cancer supply crisis meets fresh Phase III data. ImmunityBio’s Tokyo BCG deal could test how flexible U.S. regulators are willing to be.
Valar Labs FDA breakthrough nod signals new test for AI-led bladder cancer risk prediction
Bladder cancer risk tools leave gray zones. Valar Labs’ FDA breakthrough nod tests whether AI pathology can narrow them.
Why UroGen Pharma Ltd. sees UGN-103 as more than a follow-on bladder cancer therapy
UroGen Pharma Ltd.’s UGN-103 posted strong Phase 3 bladder cancer durability data. Find out what this means for NMIBC treatment and regulation.
Akari Therapeutics Plc advances AKTX-101 as RNA splicing ADC targets TROP2 resistance in oncology
Discover how AKTX-101 could redefine TROP2 ADC resistance strategies in oncology. Read the full analysis now.